GlaxoSmithKline Earnings, Revenue beat In Q2
Investing.com - GlaxoSmithKline (LON:GSK) reported on Wednesday second quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that topped expectations. GlaxoSmithKline...
Neutral
or
GlaxoSmithKline News & Analysis
-
-
GSK more upbeat on profits and COVID, investors not sure
(Reuters) -GSK forecast a smaller drop in 2021 profit on Wednesday as the drugmaker beat second-quarter earnings expectations, buoyed by a recovery in routine visits to doctors as pandemic...
-
Vaccine Demand Boosts GlaxoSmithKline's Q2 Sales, Earnings; Maintains FY21 Guidance
GlaxoSmithKline Plc's (NYSE: GSK) turnover was £8.1 billion in Q2, up 6% Y/Y (actual exchange rate AER), 15% (constant exchange rate CER). Pharmaceuticals sales reached £4.2 billion, up 3%...
-
Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment
Shares of Vir Biotechnology Inc. gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline said the European Commission purchased 220,00 doses of their...
-
GlaxoSmithKline posts Q2 earnings beat, maintains FY forecast
GlaxoSmithKline (GSK) reported better than expected quarterly results, helped by the performance of its pharmaceuticals and vaccines businesses.The company, however, reiterated its...
-
GSK Sees Smaller 2021 Profit Fall After Q2 Beat
(Reuters) -GSK forecast a smaller drop in 2021 profit on Wednesday as the drugmaker beat second-quarter earnings expectations, buoyed by a recovery in routine visits to doctors as pandemic...
-
EU Signs Deal with GSK for Supply of COVID Potential Drug
BRUSSELS (Reuters) – The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab...
-
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc. (NYSE: BIO)...
-
GlaxoSmithKline EPS beats by £0.08, beats on revenue
GlaxoSmithKline (GSK): Q2 Non-GAAP EPS of £0.28 beats by £0.08; GAAP EPS of £0.279.Revenue of £8.09B (+6.2% Y/Y) beats by £530M.Dividend of 19p/share declared for Q2 2021
-
European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of COVID-19...
-
GSK, Vir Bio ink joint procurement agreement with EC for COVID-19 treatment, sotrovimab
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) have signed a Joint Procurement Agreement with the European Commission ((EC)) to supply up to 220,000 doses of sotrovimab,...
-
FDA approves GlaxoSmithKline's Shingrix to treat certain patients with shingles
GlaxoSmithKline (GSK) announces that the U.S. FDA has approved Shingrix for the prevention of shingles in certain adult patients at increased risk of the condition.Shingles...
-
-
GlaxoSmithKline names McNamara as CEO designate of new consumer healthcare company
GlaxoSmithKline has appointed Brian McNamara, the CEO of GSK Consumer Healthcare as the CEO designate of the new Consumer Healthcare company that will have its own listing...
-
Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period - by PMI
Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) -- The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$ 69.0 billion by 2030 and is...
-
Sanofi, GlaxoSmithKline COVID-19 shot undergoes real time review in Europe
The European Medicines Agency ((EMA)) has started the rolling review of the experimental COVID-19 vaccine developed by Sanofi (SNY) and GlaxoSmithKline (GSK), the regulator said...
-
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral hypoxia-inducible factor...
-
GSK reports positive results from Phase 3 daprodustat studies in anaemia due to CKD
GlaxoSmithKline (GSK) announces positive headline results from five studies of Phase 3 ASCEND program, evaluating the efficacy and safety of daprodustat, for patients with anaemia...
-
GSK To Sell One-Third Of Its UK R&D Site For £400M
GlaxoSmithKline plc (NYSE: GSK) is planning to sell more than one-third of its 92-acre R&D site in Stevenage, the U.K. The Company is looking to sell 33 acres of the site and unlock up to...
-
-
Moderna Is Now More Valued Than Gilead, GlaxoSmithKline: How Long Did COVID-19 Vaccine Maker Take To Hit $100B?
Moderna Inc (NASDAQ: MRNA) stock is on a roll, with its vaccine-induced momentum spilling over into 2021. The Massachusetts-based company, which had a modest beginning as a tiny biotech...
-
London Markets: U.K. inflation data boosts sterling and hits shares in British multinationals
Shares in some of the U.K.’s largest multinational companies declined on Wednesday, depressed by a stronger pound after data showed that inflation jumped by more than expected in...
-
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened ... Full story available on Benzinga.com
-
-
Codexis earns a ‘significant’ milestone payment from GlaxoSmithKline
Codexis (CDXS) announced that it won a “significant” milestone payment from the U.K
-
Alector Surging on GlaxoSmithKline Deal; Analyst Remains Positive
Alector Inc. (ALEC), a clinical stage biotechnology company, has been in the headlines recently. With a market capitalization of 3.1 billion, the share price of Alector rocketed almost 89%...
-
New Nvidia Cambridge-1 supercomputer unveiled
Nvidia has built a U.K. supercomputer for scientists and drug makers that will allow researchers to model diseases, discover new medicines and advance knowledge of the human genome.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
